U.S. Markets close in 3 hrs 14 mins

Prana enrolls 1st patient in Reach2HD Phase II Huntington Disease trial

Prana Biotechnology announced that the first patient has been dosed in the "Reach2HD Trial" - a 6 month Phase IIa clinical trial testing PBT2, the company's drug in development for Huntington disease. Reach2HD, a double blind placebo controlled study, is enrolling 100 patients with early to mid-stage Huntington Disease. The Principal Investigator on the study is Dr. Ray Dorsey of Johns Hopkins University. The trial will be conducted in approximately 20 sites across the U.S. and Australia.